RCC4
MCID: RNL034
MIFTS: 18

Renal Cell Carcinoma 4 (RCC4) malady

Categories: Rare diseases, Nephrological diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Renal Cell Carcinoma 4

Aliases & Descriptions for Renal Cell Carcinoma 4:

Name: Renal Cell Carcinoma 4 50
Rcc4 50

Classifications:



Summaries for Renal Cell Carcinoma 4

MalaCards based summary : Renal Cell Carcinoma 4, also known as rcc4, is related to renal cell carcinoma. An important gene associated with Renal Cell Carcinoma 4 is DIRC2 (Disrupted In Renal Carcinoma 2). The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder.

Related Diseases for Renal Cell Carcinoma 4

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Clear Cell Carcinoma
Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma 4 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 renal cell carcinoma 10.1

Symptoms & Phenotypes for Renal Cell Carcinoma 4

Drugs & Therapeutics for Renal Cell Carcinoma 4

Drugs for Renal Cell Carcinoma 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
6
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 341031-54-7, 557795-19-4 5329102
7
Axitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 319460-85-0 6450551
8
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
10
Nicotine Approved Phase 4 54-11-5 942 89594
11
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
12
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
14
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
15
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
16
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
17
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
19
nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 946414-94-4
20
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
21
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
22
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1,Phase 2 128794-94-5 5281078
23
Azathioprine Approved Phase 4 446-86-6 2265
24
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 1 198153-51-4 5360545
25
Ribavirin Approved Phase 4 36791-04-5 37542
26
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-67-6 938
27
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 98-92-0 936
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
29
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
30 Endostatins Phase 4 71581480
31 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 interferons Phase 4,Phase 2,Phase 3,Phase 1
33 Nicotinic Acids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Anesthetics Phase 4,Phase 2,Phase 1
36 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
37 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
38 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
39 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Hypnotics and Sedatives Phase 4,Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
44 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Interferon-alpha Phase 4,Phase 2,Phase 3,Phase 1
48 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
50 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 644)
id Name Status NCT ID Phase
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
2 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4
3 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4
4 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4
5 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
6 Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Completed NCT01339962 Phase 4
7 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma Completed NCT00460798 Phase 4
8 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4
9 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4
10 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
11 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4
12 Sorafenib in Elderly mRCC Completed NCT01728948 Phase 4
13 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4
14 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
15 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4
16 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4
17 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4
18 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
19 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4
20 Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors Recruiting NCT02700568 Phase 4
21 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4
22 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Recruiting NCT01521715 Phase 4
23 Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer Recruiting NCT02081755 Phase 4
24 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4
25 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Active, not recruiting NCT01266837 Phase 4
26 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4
27 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4
28 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4
29 Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Terminated NCT01073644 Phase 4
30 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4
31 Cost Effectiveness Of Sunitinib In Central America And Caribbean Terminated NCT01033981 Phase 4
32 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4
33 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4
34 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4
35 Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load Terminated NCT00977054 Phase 4
36 A Post Marketing Surveillance As Required By Philippine Food And Drug Administration Withdrawn NCT01781442 Phase 4
37 Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer Withdrawn NCT01353794 Phase 4
38 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3
39 A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy Unknown status NCT01560195 Phase 3
40 Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer Unknown status NCT00227747 Phase 3
41 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3
42 Caphosol in Oral Mucositis Due to Targeted Therapy Completed NCT01265810 Phase 3
43 A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Completed NCT01030783 Phase 3
44 ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00420888 Phase 2, Phase 3
45 Sequential Study to Treat Renal Cell Carcinoma Completed NCT00732914 Phase 3
46 Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) Completed NCT01613846 Phase 3
47 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3
48 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
49 SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3
50 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3

Search NIH Clinical Center for Renal Cell Carcinoma 4

Genetic Tests for Renal Cell Carcinoma 4

Anatomical Context for Renal Cell Carcinoma 4

Publications for Renal Cell Carcinoma 4

Articles related to Renal Cell Carcinoma 4:

id Title Authors Year
1
Retroperitoneal recurrence of a stage 1 renal cell carcinoma 4 years following core biopsy and fine needle aspiration: possible needle tract seeding. ( 22833531 )
2013
2
Retroperitoneal recurrence of a stage 1 renal cell carcinoma 4 years following core biopsy and fine needle aspiration: possible needle tract seeding. ( 22833375 )
2013
3
The value of nephron-sparing surgery for the treatment of renal cell carcinoma 4 to 7 cm in size. ( 23221132 )
2012
4
Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less. ( 14499679 )
2003
5
[Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less in diameter]. ( 12783662 )
2003
6
Nephron sparing surgery for renal cell carcinoma 4 cm. or less in diameter: indicated or under treated? ( 9554334 )
1998

Variations for Renal Cell Carcinoma 4

Expression for Renal Cell Carcinoma 4

Search GEO for disease gene expression data for Renal Cell Carcinoma 4.

Pathways for Renal Cell Carcinoma 4

GO Terms for Renal Cell Carcinoma 4

Sources for Renal Cell Carcinoma 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....